**Supplementary Fig. 11. Forest plot of the incidence of combined death in patients with decompensated hepatitis C cirrhosis and compensated patients treated with SOF-based DAA.** The incidence of combined deaths was significantly higher in patients with decompensated than in compensated hepatitis C cirrhosis: 4.6% (95% CI: 3.1–6.3) vs. 0.5% (95% CI: 0.2–0.8), *p<*0.0001). SOF: sofosbuvir; DC: decompensated cirrhosis; CC, compensated cirrhosis; Mortality, death.

